✦ LIBER ✦

Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer

✍ Scribed by David C. Smith; Duncan I. Jodrell; Merrill J. Egorin; Roy M. Ambinder; Eleanor G. Zuhowski; Willi Kreis; Peter G. Ellis; Donald L. Trump

Publisher: Springer
Year: 1993
Tongue: English
Weight: 701 KB
Volume: 31
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00686149

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of intravenous hexamethyl

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

✍ Mark D. Hauge; Harry J. Long; Lynn C. Hartmann; John H. Edmonson; Maurice J. Web 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 192 KB

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced gastric cancer

✍ Kathy Christman; David Kelsen; Leonard Saltz; Peter G. Tarassoff 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 3 views

Long-term intravenous hydroxyurea infusi

Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial

✍ Martin S. Blumenreich; Michael J. Kellihan; U. Geetha Joseph; Kim A. Lalley; Eli 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 1 views

Background. Hydroxyurea is an S-phase specific drug. Constant exposure of tumor cells with a low Sphase fraction to the agent may result in improved cell kill. Because of its short half-life, a continuous intravenous infusion may result in better tumor exposure than intake by mouth. The goal of this

Phase II trial of ZD1694 (TomudexTM) in

Phase II trial of ZD1694 (TomudexTM) in patients with advanced pancreatic cancer

✍ Richard Pazdur; Neal J. Meropol; Ephraim S. Casper; C. Fuchs; Harold O. Douglass 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 285 KB

Phase II trial of neoadjuvant docetaxel

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer

✍ Jacqueline Vuky; Christopher Porter; Christina Isacson; Matthew Vaughan; Paul Ko 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract ## BACKGROUND: Prostate cancer trials investigating neoadjuvant hormonal therapy, followed by surgery, have demonstrated that elimination of all tumor cells from the primary site is rare. The authors report a phase 2 trial assessing the efficacy and toxicity of docetaxel and gefitinib

A phase I trial of dactinomycin intraven

A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 3 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered